A randomised, controlled trial of exit site application of MedihoneyTM Antibacterial Wound Gel for the prevention of catheter-associated infections in peritoneal dialysis patients, The HONEYPOT Study

INTERVENTION: Daily exit site application of gamma‐irradiated, commercially available, pooled antibacterial honeys including Leptospermum sp honey (Medihoney™ Antibacterial Wound Gel, Medihoney Pty Ltd, Australia; approximately 10 mg) following exit site cleaning and drying as per standard local practice for the duration of the study. Trial participants will be treated and followed up for 12 months from the entry of the last patient in the study. Recruitment is expected to take 2 years and median trial treatment and follow up is expected to be 18 months. CONDITION: Chronic renal failure Peritoneal dialysis PRIMARY OUTCOME: Time to first episode of exit site infection, tunnel infection or peritonitis (whichever comes first) SECONDARY OUTCOME: Catheter‐associated infection rates Costs Incidence of adverse reactions Occurrence of mupirocin‐resistant microbial isolates Time to first episode of peritonitis Time to first exit site infection Time to first tunnel infection Time to infection‐associated catheter removal INCLUSION CRITERIA: Receiving peritoneal dialysis. Able to give informed consent.